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Abstract Background To date, the exact prevalence of anti-β2 glycoprotein I domain I (anti-
β2GPI-DI) antibodies in patients with antiphospholipid syndrome (APS) and their role
when assessing thrombosis risk is uncertain.
Objectives To estimate the prevalence of anti-β2GPI-DI in patients with APS and to
determine whether anti-β2GPI-DI-positive individuals are at greater risk of thrombosis,
as compared with individuals without anti-β2GPI-DI, by systematically reviewing the
literature.
Methods A detailed literature search was applied a priori to Ovid MEDLINE In-Process
and Other Non-Indexed Citation 1986 to present and to abstracts from the European
League Against Rheumatism (EULAR) and American College of Rheumatology (ACR)/
Association for Rheumatology Health Professionals (ARHP ) Annual Meetings (2011–
2015).
Results A total of 11 studies, including 1,585 patients, were analyzed. Patients were
distributed as follow: 1,218 patients APS (45.4% anti-β2GPI-DI-positive; in more detail:
504 primary APS [55.4% anti-β2GPI-DI-positive], 192 secondary APS [43.2% anti-β2GPI-
DI-positive], and 522 not specified), 318 with systemic lupus erythematosus (SLE;
26.7% anti-β2GPI-DI-positive), 49 asymptomatic carriers of antiphospholipid antibodies
(aPL) (30.6% anti-β2GPI-DI-positive), and 1,859 healthy controls. When considering the
five studies eligible for thrombotic risk assessment, four studies found a significant
association of anti-β2GPI-DI-positivity with thrombotic events, whereas one study
found no predictive correlation with thrombosis (overall odds ratio [OR] for pooled
data: 1.99; 95% confidence interval [CI]: 1.52–2.6; p < 0.0001).
Conclusion We report an overall estimated median prevalence of anti-β2GPI-DI
antibodies of 44.3% in patients with APS and/or SLE and a significantly higher
prevalence among patients with APS compared with SLE alone. Anti-β2GPI-DI anti-
bodies might represent a promising tool when assessing thrombotic risk in patients
with APS.
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The antiphospholipid syndrome (APS) is an autoimmune
disorder characterized by vascular thrombosis and/or preg-
nancy morbidity (miscarriages, fetal deaths, premature
births, etc.) associated with a persistent positivity for anti-
phospholipid antibodies (aPL). The current classification
criteria for APS include three laboratory tests: lupus antic-
oagulant (LA), anticardiolipin (aCL), and anti-β2 glycopro-
tein-I (β2GPI). To prevent detection of transient antibodies,
tests must be positive on 2 occasions, at least 12 weeks
apart.1 β2GPI is hypothesized to be the main antigenic target
for aPL, especially in vascular tissues after conformational
modification.2
Although some evidence is available supporting a role for
anti-β2GPI antibodies in contributing to thrombosis and
pregnancy morbidity,3,4 their pathogenicity remains a topic
of heated discussion. In fact, not all patients positive for the
presence of anti-β2GPI antibodies develop clinical aPL-re-
lated manifestations.3 Besides, anti-β2GPI antibodies have
also been detected in a large range of autoimmune diseases,
such as multiple sclerosis,5 and nonautoimmune diseases,
such as leprosy and in childrenwith atopic dermatitis,6with
a vast heterogeneity in terms of titers and persistence.
Thisheterogeneity in thepathogenicpotential ofanti-β2GPI
antibodies might be ascribed to the molecular structure of
β2GPI, presenting multiple antigenic specificities that can be
targeted by different autoantibodies.7 β2GPI has five homo-
logous domains (DI–DV), and recently, several studies have
focused on the epitope distribution of anti-β2GPI antibodies to
identify their clinical role.8–10 The main epitope to have been
found to be associatedwith APS involves regions of DI,9,11 and
growing evidencehas resulted in the identification of DI as the
“immunodominant epitope.”10,12,13 Both in vitro and in vivo
preliminary data are in linewith this hypothesis, supporting a
role for anti-β2GPI-DI antibodies in the development of APS-
related clinical manifestations.14,15
However, the clinical role of such antibodies is still
debated, and international criteria for derivation and con-
firmation of anti-β2GPI-DI antibodies are still lacking.16 To
date, the exact prevalence of anti-β2GPI-DI antibodies in
patients with APS and the role of testing for anti-β2GPI-DI
when assessing the thrombosis risk are unclear.
In this study, we aim to estimate the prevalence of anti-
β2GPI-DI in patients with APS and to determine whether
anti-β2GPI-DI-positive individuals are at greater risk of
thrombosis when compared with individuals without anti-
β2GPI-DI by systematically reviewing the literature.
Methods
A detailed literature search has been developed a priori to
identify articles that reported findings from clinical and
laboratory studies that tested anti-β2GPI-DI antibodies.
Key words and subject terms included are as follows:
(“beta 2-glycoprotein i”[MeSH Terms] OR “beta 2-glycopro-
tein I” [All Fields] OR “beta 2 glycoprotein 1”[All Fields]) AND
domain [All Fields]. The search strategy was applied to Ovid
MEDLINE In-Process andOther Non-Indexed Citation 1986 to
present. Abstracts from the European League Against Rheu-
matism (EULAR) and American College of Rheumatology
(ACR)/Association for Rheumatology Health Professionals
(ARHP) Annual Meetings (2011–2015) were screened and
included in the analysis when meeting the inclusion criteria
and not replicating studies published elsewhere.
Studies that met the criteria to evaluate the prevalence of
anti-β2GPI-DI antibodies and their association with the
thrombotic risk in patients with APS and control populations
were systematically analyzed by two independent reviewers
(M. R. and I. C.). Disagreements were resolved by consensus;
if consensus could not be achieved, a third party (S. S.) would
provide an assessment of eligibility. As the data on eligibility
were dichotomous (eligible: yes/no), interrater agreement at
both the title and abstract review stage and the full article
review stagewas determined by calculation of Cohen’s kappa
coefficient (k ¼ 0.93).17
Literature search strategy on the prevalence of positivity
for anti-β2GPI-DI antibodies is shown in►Fig. 1.We included
in our analysis only studies reporting: (1) clinical data
referring to aPL-related manifestations, (2) laboratory data
including aCL, LA, and/or anti-β2GPI testing, and (3) anti-
β2GPI-DI antibodies testing with detailed assay methodol-
ogy, isotype analyzed, defined cutoffs of positivity for anti-
β2GPI-DI antibodies. All published series including 10 or
more patientsmeeting the aforementioned inclusion criteria
were recorded. Methods of enrollment were also analyzed.
Prevalence of anti-β2GPI-DI antibodies was compared be-
tweenpopulations by Fisher’s exact test, two-tailed, whereas
results for association of positivity and risk of thrombosis
were compared using odds ratios reported in the studies
analyzed.
This study has been performed according to PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines,18 and the relative checklist can
be supplied upon request.
Risk of Bias Assessment
Two reviewers (M. R. and S. S.) assessed the risk of bias of
individual studies using the Newcastle–Ottawa Scale (NOS)
for cohort studies, and the NOS for case–control studies. The
NOS is a scoring tool used to assess quality of evidence and
risk of bias for nonrandomized studies included in meta-
analyses.19
Comment on Excluded Studies
A total of 13 studies,20–32 including a total of 6,169 patients
(comprising a total of 533 patients with APS and 68 with
systemic lupus erythematosus [SLE]), which included testing
of anti-β2GPI-DI antibodies in diverse cohorts of patients,
were excluded from the analysis of prevalence. The exclusion
of these studies was based on (1) the impossibility of extra-
polating clinical or laboratory data, in particular when
reporting the results of anti-β2GPI-DI positivity,23,26 (2)
lack of reported data on anti-β2GPI-DI prevalence,25 (3) no
defined cutoffs of positivity,27 and/or (4) testing results
expressed only in relation to the control groups.26
Data summarizing the studies excluded from the analysis
are illustrated in ►Table 1.
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Table 1 Studies not included into the prevalence analysis and reason of exclusion
Study Year Total
number of
patients
APS SLE Reason of exclusion
Müller-Calleja et al21 2016 4979 N/A N/A No clinical data of the patients analyzed
Manukyan et al28 2016 4979 N/A N/A No clinical data of the patients analyzed
Roggenbuck et al29 2016 61 61 N/A Impossibility of extrapolating prevalence of β2GPI-DI positivity
Pengo et al22 2015 65 N/A N/A No clinical data of the patients analyzed
Willis and
Pierangeli23
2015 72 72 N/A The study compared two assays for the detection of anti-β2GPI-
DI antibodies, without describing patients’ positivity for the
test
Rodríguez-García
et al30
2015 1404 1,404 N/A Systematic review
Meneghel et al31 2015 88 88 N/A Impossibility of extrapolating prevalence of β2GPI-DI positivity
Despierres et al24 2014 439 N/A 12 Clinical data were available for 371 patients, but only 12
patients with SLE were tested for β2GPI-DI IgA
Zohoury et al26 2013 273 273 N/A In this study, β2GPI-DI positivity was only expressed as sensitivity,
specificity, and likelihood ratios compared with normal controls
Andreoli et al25 2013 154 86 28 The results were considered as OD values, and the study used
the same cohort of patients as in a study included in the analysis
Andreoli et al20 2011 154 86 28 The study used the same cohort of patients as a study included
in the analysis
de Laat et al27 2007 33 16 N/A No clinical data of the patients analyzed, no clear cutoffs of
positivity
de Laat et al32 2005 198 6 176 Impossibility of extrapolating prevalence of β2GPI-DI positivity
Abbreviations: β2GPI-DI; -β2 glycoprotein I domain I; APS, antiphospholipid syndrome; N/A, not available; OD, optical density; SLE, systemic lupus
erythematosus.
Fig. 1 Literature search strategy on prevalence of positivity for anti-β2 glycoprotein I domain I antibodies.
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Statistical Analysis
A detailed statistical analysis has been developed a priori.
Odds ratios with 95% CI (OR [95%CI]) for arterial and/or
venous thrombosis were recorded. If not available, they
were calculated, whenever possible, by means of contin-
gency tables. In case–control and cross-sectional studies,
contingency tables were used to compare the proportion of
anti-β2GPI-DI antibodies in patients with and without
thrombosis. In prospective studies, contingency tables
were established as previously reported.33,34 Briefly, if
SLE was the enrolment criterion, the OR [95%CI] was
calculated by comparing the proportion of anti-β2GPI-DI
antibodies positivity in patients who did or did not develop
thrombosis. If thrombosis was the enrolment criterion, the
OR [95%CI] was calculated by comparing the proportion of
anti-β2GPI-DI antibodies in patients with or without recur-
rent thrombosis during follow-up. If positivity for aPL was
the enrolment criterion, the OR [95%CI] was calculated by
comparing the rates of thrombosis during follow-up of
patients grouped according to different antibody types
and titers.
Results
A total of 11 studies,9,35–44 including a total of 1,585 patients,
met the inclusion criteria. Patients were distributed as
follow: 1,218 patients with APS (504 with primary APS
[PAPS], 192 with secondary APS [SAPS], and 522 not speci-
fied), 318 with SLE, 49 aPL asymptomatic carriers, and 1,859
healthy controls (HCs).
Of 11 studies, 9 differentiated patients with APS between
PAPS and SAPS, and only 5 out of 11 studies specified the
results of anti-β2GPI-DI antibodies positivity stratifying for
the presence of concomitant autoimmune diseases. Two
studies out of 11 did not specify if the patients with APS
were PAPS or SAPS.
Detection of anti-β2GPI-DI antibodies was performed
with an enzyme-linked immunosorbent assay (ELISA) in 5
out of 11 studies,9,37,41,42,44whereas 6 out of 11 studies used
a chemiluminescent immunoassay (CIA).35,36,38–40,43All stu-
dies investigated the presence of immunoglobulin G (IgG)
isotype, and one study44 investigated the presence of IgM
and IgA anti-β2GPI-DI also.
The six studies that performed testing with CIA used the
same cutoff of positivity (99th percentile: 20 chemilumines-
cence units [CU]). Regarding the studies that used ELISA,
three studies9,37,41 expressed the cutoff of positivity as
mean þ 3 standard deviation (SD) of the HC as reference,
one study44 used a cutoff at the 99th percentile of theHC, and
lastly one study42 used a cutoff at the 95th percentile of the
HC.
Data summarizing the main characteristics of the tests
used to identify anti-β2GPI-DI antibodies are provided
in ►Table 2.
None of the studies investigated persistent positivity to
anti-β2GPI-DI antibodies.
Inclusion criteria for 6 out of 11 studies35,38–40,43,44 was
based on APS diagnosis according to Sydney revised Sapporo
guidelines.1 Two out of 11 studies, although basing their
inclusion criteria on the APS diagnosis, did not specify if the
APS diagnosis met the Sydney revised Sapporo guide-
lines.36,41 One study out of 11 had as inclusion criteria the
diagnosis of SLE that met the ACR revised criteria.37 Two
studies out of 11 had as inclusion criteria the presence of
anti-β2GPI antibodies detected at least twice at least 12
weeks apart.9,42
Results of the critical appraisal of the included studies
according to NOS are shown in ►Table 3.
The overall estimatedmedian prevalence of anti-β2GPI-DI
antibodies in patients with APS and/or SLEwas 44.3% (range:
26.7–55.4%). When focusing on patients with APS (either
PAPS or SAPS), the estimated overall prevalence was high at
45.4%. Stratifying for diagnosis, a significantly higher pre-
valence of anti-β2GPI-DI antibodies was observed in patients
with APS (either PAPS or SAPS) than those with SLE without
previous history of thrombosis (45.4 vs. 26.7%; p < 0.0001).
Data regarding the prevalence analysis are summarized
in ►Table 4.
When stratifying patients for inclusion criteria used to
enroll subjects in each study, a frequency of anti-β2GPI-DI
positivity of 38.6% was found in those studies enrolling
patients with APS according to the Sapporo cri-
teria,35,38–40,43,44 25.1% in studies including patients with
SLE (according to ACR revised criteria),37 40.3% in patients
with APS (without any details about Sydney or Sapporo
criteria),36,41 and 57.9% in those studies that aimed to assess
the frequency of anti-β2GPI-DI positivity in presently anti-
β2GPI positive patients.9,42 Aswould be expected, and due to
selection bias, an overall statistically significant higher anti-
β2GPI-DI positivity was seen in the two studies that used as
inclusion criteria the presence of anti-β2GPI positivity de-
tected at least twice at least 12 weeks apart9,42 when
compared with the other studies (►Table 5).
Five out of 11 studies9,35,36,38,42 were eligible for throm-
botic risk assessment analysis, including a total of 1,014
patients. Patients were distributed as follow: 821 patients
with APS (358 with PAPS, 179 with SAPS, and 284 not
specified), 163 with SLE, 30 aPL asymptomatic carriers,
and 139 HC. Andreoli et al42 included 100 HC based on a
previous analysis to set the cutoffs at the 95th percentile
values for anti-β2GPI-DI IgG.20
Three out of 5 studies analyzed IgG isotype with QUANTA
Flash β2GPI-DI CLIA assay and used the same cutoff of
positivity that yielded a 99.5% specificity.35,36,38 Two out of
5 studies analyzed IgG isotype with ELISA.9,42 Four studies
reported a significant association between thrombotic
events and positive testing for anti-β2GPI-DI antibo-
dies.9,19,20,38 In detail, Zhang et al35 when investigating the
association between thrombotic events and anti-β2GPI-DI
antibodies, reported an odds ratio (OR) of 3.27 (95%, CI 1.59–
6.71), Agmon-Levin et al36 reported an OR of 2.54 (95%, CI
1.05–6.15) and de Laat et al9 reported an OR of 3.5 (95%, CI
2.3–5.4). Mahler et al38 reported an OR of 4 (95%, CI 1.26–
12.6) with the original cutoff of 20 CU used in the other
studies as well. Furthermore, by optimizing the cutoff of
positivity to increase the likelihood ratio (LR)þ and OR
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Table 3 Results of the critical appraisal of the included studies according to Newcastle–Ottawa Scale19
Study Newcastle–Ottawa quality assessment scale
Selection Comparability Outcome
Zhang et al35 $$$ $ $
Mahler et al38 $$$ $ $
de Craemer and Devreese43 $$$ $
Andreoli et al42 $$ $ $
Cieśla et al39 $$
Mondejar et al40 $$$ $
Cousins et al44 $$
Agmon-Levin et al36 $$$ $ $
Wahezi et al37 $$
Hunt et al41 $$ $
B. de Laat et al9 $$ $
Table 2 Characteristics of the test used to identify anti-β2GPI-DI antibodies
Study Methodology Cutoff Notes
Zhang et al35 CIA (QUANTA Flash
assay, Inova
Diagnostics)
20 CU Recombinant DI coupled to paramagnetic
beads by the use of BIO-FLASH technology
Mahler et al38 CIA (QUANTA Flash
assay, Inova
Diagnostics)
20 CU Recombinant DI coupled to paramagnetic
beads by the use of BIO-FLASH technology
de Craemer and Devreese43 CIA (QUANTA Flash
assay, Inova
Diagnostics)
20 CU Recombinant DI coupled to paramagnetic
beads by the use of BIO-FLASH technology
Cieśla et al39 CIA (QUANTA Flash
assay, Inova
Diagnostics)
19.9 CU Recombinant DI coupled to paramagnetic
beads by the use of BIO-FLASH technology
Mondejar et al40 CIA (QUANTA Flash
assay, Inova
Diagnostics)
20 CU Recombinant DI coupled to paramagnetic
beads by the use of BIO-FLASH technology
Agmon-Levin et al36 CIA (QUANTA Flash
assay, Inova
Diagnostics)
20 CU Recombinant DI coupled to paramagnetic
beads by the use of BIO-FLASH technology
Wahezi et al37 ELISA in house Mean þ 3 SD (HC) β2GPI coated on a hydrophobic plate and a
hydrophilic platea
Hunt et al41 ELISA in house Mean þ 3 SD (HC) β2GPI coated on a hydrophobic plate and a
hydrophilic plateb
de Laat et al9 ELISA in house OD (blank þ
three times SD
β2GPI coated on a hydrophobic plate and a
hydrophilic platec
Andreoli et al42 ELISA developed by
Inova Diagnostics
95th percentile (HC) Recombinant DI coupled to ELISA plates
Cousins et al44 ELISA in house 99th percentile (HC) Binding to purified wild-type and mutant re-
combinant human DI; cCoated on Nickel che-
late-coatedmicrowell plates; epitope R39–R43
Abbreviations: CU, chemioluminiscence units; DI, domain I; HC, healthy controls; ELISA, enzyme-linked immunosorbent assay; OD, optical density;
SD, standard deviation; β2GPI, β2 glycoprotein 1.
aEpitope R39–R43.
bCoated on hydrophobic microtiter plates, goat antihuman IgG alkaline phosphatase labeled antibody.
cCoated on hydrophobic and hydrophilic plates, epitope R39–R43, monoclonal mouse anti-domain I antibody (mAb 3B7).
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(cutoff of positivity: 190.2 CU) for correlation with throm-
bosis, they reported an OR of 8. Conversely, Andreoli e al42
found no significant predictive correlation with thrombosis,
but reported that patients with recurrent thrombosis
showed higher titers of anti-β2GPI-DI antibodies. When
pooling together the results of the 5 studies we calculated
a significant association between anti-β2GPI-DI positivity
and thrombotic events (mean OR 1.99; 95% CI 1.52–2.60;
p < 0.0001).
The forest plot describing data on thrombotic risk asso-
ciation with anti-β2GPI-DI positivity is shown in ►Fig. 2.
Interestingly, three studies out of 5 reported a significant
association between triple aPL positivity and anti-β2GPI-DI
positivity.35,36,42
Discussion
In this study, we report an overall median prevalence of anti-
β2GPI-DI antibodies in APS/SLE patients of 44.3%. We ob-
served a significant higher frequency of anti-β2GPI-DI in
patients with APS (45.4%) when compared with SLE patients
(26.7%). We noted an even higher prevalence of anti-β2GPI-
DI positivity in patients with PAPS (55.4%), compared with
that of patients with SAPS (43,2%). We should acknowledge
that this observation might be biased by the small sample
size of included patients with SAPS.
When separating data for inclusion criteria, we observed
an overall significantly higher anti-β2GPI-DI positivity in the
two studies that used as inclusion criteria the persistent
positivity of anti-β2GPI antibodies.9,42 This observation is in
line with the concept that being positive for anti-β2GPI
antibodies seems to increase the likelihood of also being
positive for anti-β2GPI-DI antibodies. However, Andreoli et
al, in a cohort of 159 subjects with persistently positive,
medium, or high-titer anti-β2GPI IgG, found that 105 (66%)
were positive for anti-β2GPI-DI and 35 (22%) were positive
for anti-DIV/V IgG. These observations might suggest that
approximately a third of subjects positive for anti-β2GPI
antibodies could be negative for anti-β2GPI-DI antibodies
and positive for anti-β2GPI-D-IV–V antibodies.42
In our analysis, when pooling data together, we observed
that anti-β2GPI-DI antibodies positivity doubled the risk for
thrombotic events. In detail, four out of five studies found a
significant association of anti-β2GPI-DI antibodies positivity
Table 4 Results of the prevalence study of antibodies directed against β2GPI-DI (IgG) organized by diagnosis
Diagnosis No. of patients eligible
for prevalence study
No. of patients positive
for anti-β2GPI-DI IgG
antibodies
%
APSa 1,218 553 45.4
PAPS 504 279 55.4
SAPS 192 83 43.2
SLE 318 85 26.7
aPLþ, asymptomatic 49 15 30.6
Abbreviations: aPL, antiphospholipid antibodies; APS, antiphospholipid syndrome; IgG, immunoglobulin G; PAPS, primary antiphospholipid
syndrome; SAPS, secondary antiphospholipid syndrome; SLE, systemic lupus erythematosus; β2GPI-DI, β2 glycoprotein 1 domain I.
aAPS group includes 504 with primary APS, 192 with secondary APS, and 522 not specified.
Table 5 Data of the two studies that used persistent anti-β2GPI positivity as inclusion criteria compared with data excluding the
two studies
DIAGNOSIS No. of patients
eligible for
prevalence
study
No. of patients
positive for
anti-β2GPI-DI
IgG antibodies
% P (Fisher’s exact test)
A B A B A B
APSa 451 767 279 274 61.9 35.7 <0,0001
PAPS 323 181 225 54 69.7 29.8 <0,0001
SAPS 128 64 54 29 42.2 45.3 0.7577
SLE 93 190 36 31 38.7 16.3 <0,0001
aPLþ, asymptomatic 30 19 13 2 43.3 10.5 0.0955
Abbreviations: aPL, antiphospholipid antibodies; APS, antiphospholipid syndrome; IgG, immunoglobulin G; PAPS, primary antiphospholipid
syndrome; SAPS, secondary antiphospholipid syndrome; SLE, systemic lupus erythematosus; β2GPI-DI, β2 glycoprotein 1.
A: Data only of the two studies that used persistent anti-β2GPI positivity as inclusion criteria.
B: Data excluding the two studies that used persistent anti-β2GPI positivity as inclusion criteria.
aAPS group includes 504 with primary APS, 192 with secondary APS, and 522 not specified.
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with thrombotic events, whereas one study found no pre-
dictive correlation with thrombosis. However, one could
speculate that these findings might be at least in part
explained by the fact that anti-β2GPI-DI antibodies levels
have been shown to be significantly higher in individuals
with a triple-positive aPL profile, a well-identified category
at increased risk for thromboembolic events.22
A common limitation of the studies that analyze non-
criteria aPL is the small sample size. However, we found that
7 out of 11 studies eligible for prevalence analysis included a
large cohort of patients (>100), supporting the strength of
the observation. Similarly, our analysis included a total of
1,809 (range: 30–200) HC.
In the studies analyzed, two different laboratory tests
were used to identify anti-β2GPI-DI antibodies (6 out of 11
studies used CLIA and 5 used ELISA). Some intrinsic differ-
ences due to the techniques might be speculated. However,
recently, Willis and Pierangeli23 reported a good qualitative
(k ¼ 0.6) and quantitative (Spearman’s rho ¼ 0.76) agree-
ment between two laboratory tests: ELISA in house Univer-
sity College London and QUANTA Flash CIA (Inova
Diagnostics).
Nevertheless, despite the reported good agreement be-
tween the two test types, some additional considerations are
worth mentioning. First, it is reasonable to suspect that the
antigenic preparations (conformational peptide versus
whole DI) could influence the test’s ability to detected
anti-β2GPI-DI antibodies. This difference might intrinsically
influence the level of agreement between the studies con-
sidered in our analysis. Second, anti-β2GPI-DI testing might
be influenced by the conformational changes of β2GPI that
directly modify the exposure to the surface of DI.45 In fact,
anti-β2GPI-DI antibodies have reactivity toward their target
epitope only when DI is coated onto hydrophobic, but not
hydrophilic plates.32 Unfortunately, there is no study avail-
able that has specifically compared the concordance among
techniques using different antigen preparations.
Clinical manifestations of APS include vascular thrombo-
sis and/or pregnancy morbidity. In our review, we analyzed
the thrombotic risk assessment in relation to anti-β2GPI-DI
antibodies positivity; however, no studies have reported a
predictive association betweenpregnantmorbidity and anti-
β2GPI-DI positivity to our knowledge.
Recently, Müller-Calleja et al21 investigated IgG anti-
β2GPI-DI antibodies positivity with CIA in a large cohort
of individuals (4,979 and 1,049 HC) to estimate the overall
positivity in the general population. Although no significant
difference was reported between the whole sample of
individuals of the general population and the HCs, no
detailed clinical data of the individuals included in the
study was provided. Thus, although the general population
is unlikely to benefit from indiscriminate screening for
these antibodies, their detection in patients with SLE,
connective tissue diseases, and/or previous thrombosis is
justified by the high thrombotic risk associated with these
clinical conditions.42
Strengths and Limitation of the Analysis
The strengths of this analysis lie on a priori designed search
strategy, and the inclusion of gray literature searches and
manual review of reference lists minimized the risk of
missing eligible studies. We performed independent and
duplicate review for study selection and data extraction.
However, there are also limitations. All of the included
studies were observational studies, subject to the biases
inherent in such study designs.
Our research strategy did not include Scopus as per a
priori designed protocol. Additionally, there was heteroge-
neity in the data in terms of inclusion criteria, assay hetero-
geneity, cutoff values definition, detected Ig isotypes, clinical
details, control groups, and site of thrombosis. Moreover,
none of the studies reported data comparing persistent
versus transient anti-β2GPI-DI positivity. Also, only a min-
ority of studies confirmed their findings by multivariate
analysis. Furthermore, when analyzing the control groups
used in the studies included in the analysis, no study
included a control group consisted of event-free aPL carriers,
limiting the generalizability of the role of anti-β2GPI-DI
Fig. 2 Forest plot of thrombotic risk association with anti-domain I positivity.
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positivity in the different subgroups (e.g., thrombotic APS,
obstetric APS, isolated aPL carries, aPL carriers in patients
with SLE). Finally, while significant international improve-
ments have been achieved in the standardization of IgG and
IgM anti-β2GPI antibody measurement,46,47 one could not
exclude that some potential bias related to the availability of
existing reference materials might still exist.
Conclusions
Despite the limitations of the studies included, we report an
overall estimated median prevalence of 44.3% in patients
with APS and/or SLE and a higher prevalence of anti-β2GPI-DI
antibodies among patients with APS compared with SLE
alone. Furthermore, when pooling data together, we ob-
served that anti-β2GPI-DI antibodies positivity doubles the
thrombotic risk compared with patients negative for anti-
β2GPI-DI antibodies.
Thus, anti-β2GPI-DI antibodies seem to be a potential
candidate as a laboratory tool for the diagnosis of APS, in
particular regarding thrombotic risk assessment. The inclu-
sion of anti-β2GPI-DI antibodies as laboratory criteria for the
APS should be indubitably explored.
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